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The Agency for Toxic Substances and Disease Registry (ATSDR) is a public health agency with
responsibility for assessing the public health implications associated with uncontrolled releases of
hazardous substances into the environment. The biological effects of low-level exposures are a
primary concern in these assessments. One of the tools used by the agency for this purpose is the
risk assessment paradigm originally outlined and described by the National Academy of Science in
1983. Because of its design and inherent concepts, risk assessment has been variously employed
by a number of environmental and public health agencies and programs as a means to organize
information, as a decision support tool, and as a working hypothesis for biologically based
inference and extrapolation. Risk assessment has also been the subject of significant critical
review. The ATSDR recognizes the utility of both the qualitative and quantitative conclusions
provided by traditional risk assessment, but the agency uses such estimates only in the broader
context of professional judgment, internal and external peer review, and extensive public review
and comment. This multifaceted approach is consistent with the Council on Environmental
Quality's description and use of risk analysis as an organizing construct based on sound biomedical
and other scientific judgment in concert with risk assessment to define plausible exposure ranges
of concern rather than a single numerical estimate that may convey an artificial sense of precision.
In this approach biomedical opinion, host factors, mechanistic interpretation, molecular
epidemiology, and actual exposure conditions are all critically important in evaluating the
significance of environmental exposure to hazardous substances. As such, the ATSDR risk
analysis approach is a multidimensional endeavor encompassing not only the components of risk
assessment but also the principles of biomedical judgment, risk management, and risk
communication. Within this framework of risk analysis, the ATSDR may rely on one or more of a
number of interrelated principles and approaches to screen, organize information, set priorities,
make decisions, and define future research needs and directions. Environ Health Perspect
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Introduction
The Agency for Toxic Substances and Human Services. TheATSDR mission is to
Disease Registry (ATSDR) is one ofeight prevent exposure and adverse human health
agencies ofthe U.S. Public Health Service effects and diminished quality oflife associ-
within the U.S. Department ofHealth and ated with exposure to hazardous substances
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from waste sites, unplanned releases, and
other sources ofpollution present in the
environment (1). Pursuant to its responsi-
bilities mandated by the Comprehensive
Environmental Response, Compensation,
and LiabilityAct, also known as Superfund,
the agency addresses public health concerns
associated with a wide range of low-level
exposures to substances found at hazardous
waste facilities.
The ATSDR, like other agencies such as
the U.S. Environmental Protection Agency
(U.S. EPA) and the U.S. Food and Drug
Administration (U.S FDA), has relied on
risk assessment in its task ofassessing the
public health implications oflow-level expo-
sures to hazardous substances. As defined by
the National Academy ofSciences in 1983,
risk assessment consists offour interrelated
steps or components: hazard identification,
dose-response assessment, exposure assess-
ment, and risk characterization (2). In the
real-life risk assessment process, the fourth
step, risk characterization, is actually an
integration ofthe other three components
into a qualitative and/or quantitative assess-
ment that characterizes the probability of
adverse health effects in an exposed popula-
tion. The ATSDR approach for risk charac-
terization of noncancer adverse health
effects is primarily a qualitative rather than a
probabilistic undertaking. Nevertheless, the
ATSDR does use minimal risk levels
(MRLs), health guidance values developed
by the ATSDR specifically to identify levels
ofexposure thought to be without apprecia-
ble risk over specified durations and routes
ofexposure (3). Although the procedures
used to derive such health guidance values
by agency scientists is operationally straight-
forward, the judgment that goes into devel-
opment ofthese values is guided by a full
range ofexpert judgment in the fields of
toxicology, epidemiology, and pathology, as
detailed below.
In this paperwe discuss the role ofhealth
guidance values in public health practice and
the application ofmechanistic insights in
deriving health guidance values. Three ques-
tions posed are vital to how regulatory and
public health agencies consider the biological
effects oflow-level exposures (4):
* Does the understanding of the mecha-
nisms of toxicity affect how agencies
assess risks from exposures to toxic sub-
stances?
* Does an understanding of the mecha-
nisms by which the body adapts (e.g.,
detoxifies, repairs, etc.) to the effects of
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exposures to toxic substances affect how
the ATSDR assesses risks from exposures
to toxic substances?
If low doses of toxic agents induce
apparently beneficial responses (e.g.,
enhanced longevity, lower incidence of
disease), how does and/or could the
ATSDR address this?
We conclude these discussions by out-
lining some future directions being pursued
by the ATSDR to expand and strengthen
the practical application of biologically
based inference and extrapolation to the
risk characterization and analysis of envi-
ronmental exposures to hazardous wastes.
Risk Analysis as an
Organizing Construct to
Promote Optimal Decisions
The ATSDR uses risk assessment and
associated health guidance values in the
context of risk analysis as defined by the
Council on Environmental Quality (5).
Within this framework, risk analysis is an
organizing construct based on sound bio-
medical and other scientific judgment as
well as on risk assessment and is used to
define plausible ranges of concern rather
than single numerical conclusions, which
often are misinterpreted. In this approach
actual exposure conditions are critically
important to the process of evaluating the
significance ofenvironmental exposures to
hazardous substances (6).
As applied by the ATSDR in public
health practice, risk analysis is a multidi-
mensional endeavor encompassing the
concepts of risk assessment, biomedical
judgment, risk management, and risk
communication (Figure 1). Its application
can be visualized within the broader con-
text of the agency's public health assess-
ment program (Figure 2). As part of its
public health mission, the ATSDR devel-
ops public health assessments to evaluate
the public health implications of all haz-
ardous waste sites on the National Priorities
List (NPL) and for selected sites identified
by public petition (1). The ATSDR's pub-
lic health assessments are based on three
key components: environmental monitor-
ing data, health outcome data, and com-
munity health concerns. These three
components are then evaluated in the con-
text ofwhat is known about the toxicity of
site-related contaminants, the probability
of past, present, or future exposures, and
the significance ofsite-specific conditions,
including demographic and other parame-
ters of exposure. In these evaluations the
ATSDR may use health guidance values
/
Figure 1. Risk analysis as a multidimensional
endeavor, encompassing the components of risk
assessment, biomedical judgement, risk management,
and risk communication.
specifically to determine which chemicals
should be addressed further in terms of
risk posed to exposed communities based
on a comparison with environmental mon-
itoring data. Depending on the outcome of
the ATSDR analysis, a number of follow-
up activities might be considered. Possible
follow-up activities may include further
health study and/or surveillance, health
education, research, and the development
ofchemical-specific exposure registries.
Derivation of Health
Guidance Values
The ATS.DR derives chemical-specific
health guidance values known as MRLs for
oral and inhalation routes of exposure to
assist and guide health assessors in evaluat-
ing contaminants of concern at hazardous
waste sites. An MRL is defined as "an esti-
mate of the daily human exposure to a
substance that is likely to be without an
appreciable risk ofadverse, noncancer effects
over a specified duration ofexposure" (3).
Depending on the availability ofappropriate
data, MRLs are calculated for both oral and
inhalation routes of exposure and for three
specific durations of exposure: acute (1 to
14 days), intermediate (15 to 364 days), and
chronic (365 days or longer).
These MRLs, their supporting databases,
and an explanation offactors considered in
their derivation are included in toxicologi-
cal profiles developed by the ATSDR (7).
Procedurally, the derivation of an MRL is
straightforward and analogous to the deriva-
tion ofacceptable daily intakes (ADIs) and
Figure 2. Application of the concept of risk analysis to
the ATSDR public health assessment program.
reference doses/reference concentrations
(RfDs/RfCs) developed by the U.S. FDA
and the U.S. EPA, respectively. Specific
internal guidance for derivation of MRLs
by the ATSDR has been published (3).
Traditionally, health guidance values
have been derived from either controlled
human clinical studies, human epidemio-
logic studies (usually retrospective), or con-
trolled studies involving laboratory animals
serving as surrogates for human popula-
tions. Based on a review of these studies,
the lowest dose or exposure level at which
an effect considered adverse was observed
(LOAEL) and the highest level below
which no adverse effect was observed
(NOAEL) is similarly determined. Because
the population of interest in the health
study typically is not the same as a poten-
tially exposed population to be protected
by the health guidance value, mathematical
adjustments are made to the LOAEL or
NOAEL to express uncertainties inherent
in the assumptions and database used to
calculate the health guidance value.
The uncertainty factors (UFs) proposed
by Barnes and Dourson (8) and presented
in Table 1 provide the basis for the approach
and types of mathematical adjustments
used by the ATSDR in deriving its MRLs.
Each MRL thus has its own area of uncer-
tainty with regard to its derivation based
primarily on the study used as the basis for
deriving the MRLs. The aggregate UFs can
be viewed as loose upper-bound estimates
that account for differences in susceptibil-
ity between test and target species and for
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Table 1. Factors used by the ATSDR in derivation of
MRLs.
UFs and MFsa Used to account forb
3-10 Extrapolation from animal
studies to humans
(interspecies differences)
1-10 Differences in sensitivity
among humans
(intraspeciesvariability)
3-10 Use of an LOAELrather
than an NOAEL
>0-10 Completeness of database
Abbreviatiom: MF, modifying factor. aMaximum fac-
tors used to date in MRL derivation is 3000. bThe
ATSDR does not at this time extrapolate between
exposure routes.
sensitivity differences within the human
population. The overall magnitude of the
UF reflects the confidence in the final cal-
culated number and the database support-
ing that number for a given chemical. As a
result the final health guidance value, or
MRL, can be viewed as an estimate of a
dose that is likely to be without adverse
effects in sensitive individuals for a specified
duration and route ofexposure.
Mathematically the derivation of the
MRL can be expressed as follows:
MRL = the NOAEL or LOAEL
UFxMF
where MF = a modifying factor and the
NOAEL, the LOAEL, and the UF are as
previously defined.
This formula provides a computational
method for determining a reference value
for a particular substance and a particular
route and duration of exposure. MRLs
thus derived provide route-specific guid-
ance that would protect all potentially
exposed populations. As such, they also
provide a basis for determining screening
or trigger levels for chemical-specific expo-
sures of concern on a site-specific basis.
Health guidance values such as MRLs,
RfDs/RfCs, and ADIs can all be used in
specific exposure scenarios to estimate lev-
els of a substance in a particular environ-
mental medium that can serve as a basis to
determine whether further evaluation is
warranted. Such health guidance values as
used by the ATSDR are intended to be
used only as screening tools. They are not
intended to be interpreted as precise values
or used as action levels but as indicators of
whether further evaluation is warranted for
a particular exposure scenario. Moreover,
because of the specific exposure route,
exposure duration, and toxicity end point
associated with each health guidance value,
the values can also be used to alert health
care providers about what outcomes they
should be concerned with in a particular
locality or site vicinity.
The Role of Biomedical
Judgment in Derivation
of Health Guidance Values
Although procedures used by agency
scientists to derive health guidance values
are operationally straightforward, the judg-
ment used in developing these values is
guided by a full range of expertise in the
fields of toxicology, epidemiology, and
pathology, as detailed below.
Application ofMechanistic Insights
in theDerivation ofHealth
GuidanceValues
With regard to the first question posed in
"Introduction," an understanding of the
mechanism of toxicity affects how the
ATSDR assesses risks from exposure to
toxic substances. Because reactions between
toxic chemicals and organisms are interac-
tive processes, several issues must be con-
sidered when evaluating mechanisms of
toxicity for risk-assessment purposes. First,
how does the organism affect the chemical
being evaluated in terms of toxicokinetic
mechanisms (i.e., absorption, distribution,
metabolism, and excretion)? Differences in
the toxicokinetics ofvarious chemicals, and
similarly, interspecies differences in the
toxicokinetics of the same chemical, may
account for significant variations in toxic-
ity. Second, how does the chemical affect
the organism in terms of toxicodynamic
mechanisms (e.g., interacting with specific
receptors, enzymes, membrane sites, or
other proteins)? In addition, after initial
chemical insult, further chemical exposure
and subsequent biochemical reactions may
lead to toxicologically significant morpho-
logical changes. The ATSDR's multifac-
eted risk-assessment approach requires full
consideration ofsuch mechanistically based
differences and similarities in the patho-
genesis ofdisease. These considerations are
especially important to the process ofeval-
uating and selecting appropriate toxicity
end points for the derivation ofMRLs.
Toxicokinetic Mechanisms. Several
examples in which the ATSDR used a
knowledge ofchemical-specific toxicokinetic
mechanisms in derivation of its MRLs are
listed and discussed below. These examples
are summarized in Table 2.
Absorption/Bioavailability. 2,3,7,8-
TETRACHLORODIBENZO-P-DIOXIN (TCDD).
TheATSDRhas developed a proposed acute
oral MRL for TCDD based on a study in
mice exposed to 14 daily doses ofTCDD by
gavage in oil vehicle (9). An important issue
considered during derivation ofthis MRL
was the bioavailabilityofTCDD (10): It has
been well documented in animal studies that
adsorption ofTCDD from the gastrointesti-
nal tract depends largely on the carrier vehi-
cle (11). Absorption ofTCDD from both
soil and feed has been estimated to be 20 to
60%, whereas the adsorption ofTCDD
from a corn oil vehicle has been estimated to
be as much as 85%. Because the likely
means ofenvironmental exposure to TCDD
is through ingestion ofcontaminated food or
soil but the definitive animal TCDD toxicity
study used corn oil gavage, MRL derivation
Table 2. Mechanistic insights affecting derivation of MRLs: toxicokinetics.
Chemical Toxicokinetic mechanism Description
TCDD Absorption Differences in absorption using soil, feed, or oil
vehicle; reflected in the use of MF
Cyanides Metabolism Interspecies differences in tissue levels of
rhodanesea; very low in dogs
PCE Metabolism Interspecies differences in metabolism of PCE to
TCA; more TCA in mice than in humans
TCE Distribution/excretion Not readilyeliminated, accumulation in adipose
tissue; adjustmentfor continuous exposure
1,1,1,-Trichloroethane Distribution/excretion Rapidly eliminated, blood levels plateau after
2 to 3 hr; no adjustment for continuous exposure
Hexachlorethane Distribution/excretion Rapid turnover in tissues; no adjustment for
continuous exposure
Vinyl chloride Distribution/excretion Rapidly metabolized and excreted, readily reaches
steady state; no adjustment for continuous exposure
Abbreviations: PCE, tetrachloroethylene; TCA, trichloroacetic acid; TCE, trichloroethylene; TCDD, 2,3,7,8-tetra-
chlorodibenzo-p-dioxin. aAn enzyme used in the conversion of cyanide into inactive thiocyanate.
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was divided by an additional modifying
factor of0.5 to adjust for the approximate
2-fold greater bioavailability from corn oil
compared to thatfrom food orsoil.
Metabolism. Many toxic chemicals are
metabolized by similar metabolic pathways
across species. However, interspecies differ-
ences are also well documented (12). These
differences often are attributed to lack of
particular enzymes or differences in the rel-
ative importance ofparticular routes of
metabolism. Cyanides and tetrachloroeth-
ylene (PCE) are examples of chemicals
with specific mechanistic differences in
metabolism that affected derivation ofthe
ATSDR MRL.
CYANIDES. Rhodanese is an enzyme
used in the conversion ofcyanide into inac-
tive thiocyanate. Dog tissues have low levels
ofrhodanese compared with levels in other
species; therefore dogs are extremely suscep-
tible to cyanide poisoning. As a result,
cyanide metabolism in a species such as the
rat more accurately reflects cyanide metabo-
lism in the human than does cyanide
metabolism in the dog. Because ofthis, the
ATSDR based its intermediate-duration
oral MRL on a study in rats even though a
similar study in dogs reported much lower
toxic effect levels (13).
TETRACHLOROETHYLENE. During the
ATSDR derivation ofMRLs for intermedi-
ate-duration inhalation and oral exposures to
PCE, it was noted that the proposed toxic
end point reported for mice (peroxisomal
proliferative response in the liver) might not
be relevant to humans. Several differences in
PCE metabolism exist between mice and
humans. The rate ofmetabolism ofPCE to
trichloroacetic acid (TCA)-the reactive
metabolite in the hepatic toxicity-is much
greater in mice than in humans (14).
Moreover, mice and rats also respond to
TCA and many other chemicals by induc-
tion ofhepatocellular peroxisomes, whereas
humans either are much less responsive to
peroxisome proliferators or do not respond
at all to doses that cause marked responses in
rodents. Because humans produce little TCA
following PCE exposure and because peroxi-
somal proliferation in humans is minimal
compared to that in rodents, liver hypertro-
phy and tumor development as observed in
mice may not occur by the same mechanism
in humans or may be much less likely to
occur. Therefore, theATSDRdid not derive
intermediate-duration MRLs for PCE from
these rodent studies but instead deferred
derivation until the significance of these
mechanistic differences between humans and
rodents is more filly understood.
Distribution and Excretion.
According to the ATSDR MRL methodol-
ogy (3), ifa study serving as the base for an
MRL derivation does not involve continu-
ous dosing over the entire exposure period,
an adjustment can be made to correct for
intermittent exposure. Generally, the inter-
mittent exposure dose is multiplied by cor-
rection factors to adjust for a full 24 hr/day
and 7 days/week ofexposure.
More specifically, ifstudy results indicate
that a toxic end point depends directly on
the duration ofexposure (e.g., ifmetabolism
and excretion is moderate to slow or the
study results indicate that the toxic end point
is acumulative effect), adjustments to correct
for intermittent exposure may be appropri-
ate. Conversely, ifthe critical effects are con-
sidered to depend mainly on exposure
concentration rather than length ofexposure
and ifthe substance being tested is rapidly
metabolized and/or eliminated, dose adjust-
ment for intermittent exposure generally is
considered inappropriate. A number of
examples are presented below in which the
ATSDR considered the appropriateness of
dose adjustment for intermittent exposure in
derivation ofMRLs.
TRICHLOROETHYLENE. An acute-
duration inhalation MRL was derived for
trichloroethylene (TCE) based on neurologic
effects observed in human volunteers (15).
An intermediate-duration inhalation MRL
was also derived from a study in which neu-
rological effects were seen in rats (16).
Because the toxicokinetic data indicate that
TCE is not readily eliminated and can accu-
mulate in adipose tissue (17), both MRLs
wereadjusted forintermittent exposure.
1,1,1-TRICHLOROETHANE. An acute-
duration inhalation MRL was derived for
1,1,1-trichloroethane based on an LOAEL
for reduced performance on psychomotor
tests reported in humans (18). However,
1,1,1-trichloroethane is rapidly eliminated
in the expired air and blood levels of 1,1,1-
trichloroethane plateau after 2 to 3 hr (18).
These findings suggest that longer exposure
would not lead to higher body burdens.
Therefore, a correction for intermittent
exposure was considered inappropriate for
the acute-duration inhalation MRL for
1,1,1-trichloroethane (19).
HEXACHLOROETHANE. An acute-
duration inhalation MRL was derived for
hexachloroethane based on an NOAEL for
neurological effects reported in pregnant
rats exposed to hexachloroethane (20).
Laboratory data showed that effects depend
on blood levels, which directly depend on
concentration, not duration of treatment
(21). Moreover, the toxicokinetic data also
showed a rapid turnover in the tissues.
Therefore, no adjustment was made to the
MRL to correct for intermittent exposure.
VINYL CHLORIDE. An acute-duration
inhalation MRL was derived for vinyl chlo-
ride based on developmental effects in
offspring of mice exposed during gesta-
tion (22,23). An intermediate-duration
inhalation MRL was also derived based on
hepatic effects in rats (24). A review ofthe
toxicokinetic data indicated that vinyl chlo-
ride readily reaches steady state, is rapidly
metabolized and excreted, and neither it nor
its metabolites readily accumulate in tissue
(25). Therefore, no adjustment for intermit-
tent exposure was made in the derivation of
either the acute or the intermediate-duration
inhalation MRLforvinyl chloride.
Toxicodynamic Mechanisms. Chemical
interactions with specific receptors or
enzymes are examples of toxicodynamic
mechanisms. Such mechanisms and their
associated interspecies differences may play
critical roles in the expression oftoxicity as
well as in deliberations about riskassessment
for toxic chemicals. Two specific examples
ofhow understanding such toxicodynamic
mechanisms has affected the ATSDR
derivation ofMRLs are discussed below.
Chlorinated Dibenzodioxins and
Dibenzofurans. Chlorinated dibenzodioxins
(CDDs) and chlorinated dibenzofurans
(CDFs) are groups ofhalogenated aromatic
hydrocarbons that are closely related chemi-
cally and often occur together in the
environment (26). To estimate the risk asso-
ciated with exposure to chemical congeners
ofthese two dosely related chemical dasses,
the ATSDRhas adopted the U.S. EPA toxi-
city equivalency factors (TEF) method,
which is based on congener-specific data and
the assumption that Ah receptor-mediated
toxicity is common to dioxinlike congeners
and is additive (27). The TEF scheme com-
pares the relative toxicity ofindividual CDD
and CDF congeners to that of 2,3,7,8-
TCDD, the most toxic and extensively
studied ofthesehalogenated aromatichydro-
carbons. The TEF for 2,3,7,8-TCDD is
defined as unity, whereas TEF values for all
other CDD and CDF congeners are less
than 1 (0 has been assigned to all non-
2,3,7,8-substituted congeners); this reflects
the lower toxic potency ofmost CDD and
CDF congeners. A description of the
ATSDRMRLvalues for a number ofCDDs
and CDFs using the TEF approach was
recently published in an article that also
points out a number of uncertainties
associatedwith this method (28).
Environmental Health Perspectives * Vol 106, Supplement 1 * February 1998 372PUBLIC HEALTH IMPLICATIONS OF ENVIRONMENTAL EXPOSURES
METHYL-T-BUTYL ETHER. An MRL for
chronic-duration inhalation exposure to
methyl-t-butyl ether (MTBE) was derived
from an NOAEL for chronic progressive
nephropathy in female rats (29). Chronic
progressive nephropathy is an age-related
spontaneous disorder of rats that is more
severe in males than in females and affects
certain strains more than others (30).
Chronic exposure ofmale rats to ac2,-glob-
ulin-inducing agents results in aggravation
ofchronic progressive nephropathy, which
is characterized by increased severity and
earlier onset ofthe disease. Based on these
considerations, the ATSDR concluded that
the higher incidence and greater severity of
chronic progressive nephropathy observed at
lower MTBE exposure concentrations in
male rats compared with that in female rats
may have been due to exacerbation ofthis
syndrome bythe accumulation ofa2p-glob-
ulin or another unknown protein unique to
male rats. As aresult this end pointwas con-
sidered unsuitable for MRL derivation.
However, because female rats also exhibited
enhanced chronic progressive nephropathy
but at higher exposure levels, the NOAEL
for this end point in female rats was
used (instead ofthe NOAEL observed in
male rats) to derive the chronic-duration
inhalation MRL for MTBE.
AssessmentofAdaptiveResponses
intheDerivationofHealth
GuidanceValues
In response to the second question posed
in "Introduction," understanding the
mechanisms by which the body adapts to
the effects ofexposure to toxic substances
affects how the ATSDR assesses risk from
exposure to toxic substances. Many poten-
tially toxic chemicals cause changes in an
organism that may be considered adaptive.
In other words, the organism responds
to the chemical exposure in a way that
maintains homeostasis.
Adaptive responses within organisms
may involve biochemical or structural
alterations. Examples ofadaptive biochem-
ical responses include induction of the
cytochrome P450 mixed-function oxidase
system in the liver or other organs as well
as glutathione depletion and synthesis in
the liver. Examples ofstructural adaptive
responses within tissues include atrophy,
hypertrophy, hyperplasia, and metaplasia.
Adaptive responses generally are considered
to enhance an organism's performance or
its ability to withstand challenge. Actually,
however, some alterations that typically are
classified as adaptive responses may have
potentially harmful (i.e., adverse) effects on
the host in some cases. An adverse effect is
defined as "any effect that reduces the
capacity ofan organism or a component of
the organism to function in a normal man-
ner or diminishes the ability to withstand
further stress" (31).
Classification of biologic changes in
tissues often is challenging. For example,
the borders between hyperplasia and neo-
plasia and between benign and malignant
neoplasia often are indistinct. Similarly, the
boundary between adaptive and toxic
responses often is not well delineated. As a
result biologic assessment of adaptive
responses as adverse or not adverse is a mat-
ter ofjudgment and sometimes is contro-
versial. Hypertrophy ofskeletal muscle in
response to increased workload is an exam-
ple ofan adaptive change that might prove
beneficial to the host. However, hypertro-
phy of the left heart ventricle because of
arterial hypertension, even though it allows
the heart to function against an increased
workload, will result in decreased cardiac
ability to compensate for additional stress.
Metaplasia also typically is considered an
adaptive response but the predictive value
for lesion progression and secondary effects
is not always clear. Ifmetaplasia occurs in
the pancreas (e.g., squamous metaplasia of
pancreatic ducts associated with exposure
to a test substance), this process generally
does not interfere with pancreatic function.
However, ifsquamous metaplasia occurs in
the tracheal epithelium it may interfere
with normal respiratory defense function
(mucociliary escalator).
A common biochemical adaptive
response is induction ofthe cytochrome
P450 mixed-function oxidase system
(32-34). Many chemicals evaluated by the
ATSDR (e.g., aldrin, chloroform, DDT,
PCE) can induce the cytochrome P450 sys-
tem in the liver or other organs. This induc-
tion leads to stimulation ofprotein synthesis
and proliferation ofsmooth endoplasmic
reticulum. Depending on the inducing
agent, one or more isoenzymes ofP450 may
be induced, each ofwhich has different
affinities for a variety ofother substances.
The P450 system plays a critical role in the
metabolism ofboth endogenous and exoge-
nous compounds. In some cases, as in aceta-
minophen or carbon tetrachloride, this can
be viewed as a toxification reaction (i.e., the
parent compound is metabolized to a more
toxic species). In other cases, as with ethanol
or phenobarbital, the cytochrome P450 sys-
tem detoxifies the parent compound, which
results in less reactive metabolites. However,
once induction of the mixed-function
oxidase system has occurred (no matterwhat
chemical was the initiater), this adaptive
response has significant implications in
future chemical exposures. This adaptive
modification may potentiate or inhibit toxic
responses to subsequent chemical exposures.
The enhancement or inhibition ofa com-
pound's metabolism can lead to toxicological
interactions that may be important in site-
specific risk assessments (35). This concept
is particularly significant to the ATSDR in
its assessment ofNPL sites, where multi-
chemical exposures are much more likely
than exposure to asingle chemical.
Within the framework ofhuman health
risk assessment, hepatic cytochrome P450
induction generally should be classified as
an adverse effect. This induction alters the
normal functioning ofthe organ (i.e., the
organ is able to metabolize compounds at a
greater rate). Even though this effect may
be beneficial for some compounds it may
be detrimental for others. Additionally, the
designation of P450 induction as an
adverse effect reflects the judgment that
involuntary environmental exposure to
chemicals should not be at levels that alter
the normal state ofthe organism.
Glutathione depletion in the liver is
another example ofa biochemical adaptive
response. The hepatic metabolism of
chemicals such as acetaminophen can
result in such depletion. Acetaminophen is
metabolized bycytochrome P450 to a reac-
tive intermediate that is detoxified by con-
jugation with glutathione (36). As long as
levels ofglutathione are not depleted, no
hepatotoxic effects are induced. However,
high doses ofacetaminophen result in glu-
tathione depletion, after which overt toxic
effects are likely in the liver. Such chemi-
cal-induced depletion ofliver glutathione is
considered an adverse effect because it
diminishes the normal capacity ofthe liver
to respond to other chemical agents.
Clearly, P450 induction and glutathione
depletion are not frank toxic effects. At the
whole-organism or whole-organ levels no
damage may be apparent. Consequently,
adaptive or compensatory changes such as
P450 induction or hepatic glutathione
depletion are most appropriately dassified as
minimal adverse effects. Ifexposures causing
such effects are associated with more severe
responses, the nature of these responses
rather than the associated adaptive changes
should be used to evaluate toxicity at that
level ofexposure.
To be consistent with the ATSDR's
public health mission of preventing and
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mitigating adverse health effects caused
by exposure to hazardous substances, it is
important to assess adaptive responses to
chemical exposures on a case-by-case basis.
Within the definitions presented earlier
and the general context of risk analyses
involving chemical contamination, an
adaptive response may be classified as
adverse when the adaptive alteration poten-
tially contributes to frank toxic effects,
when it diminishes the organism's abilitv
to withstand further stress, orwhen it com-
promises an organism's normal ability to
dispose ofchemical substances.
All these criteria are individually and
collectively considered by the ATSDR in
assessing the risk posed by exposure to
toxic substances. Adaptive response may
actually be the basis for selecting the toxic
end points the ATSDR uses in its deriva-
tion ofhealth guidance values. Moreover,
the understanding and interpretation of
such adaptive responses may also affect
how the agency evaluates multiple chemi-
cal exposures at complex waste sites.
Clearly, an in-depth understanding ofadap-
tive mechanisms is crucial to the ATSDR's
multifaceted risk-assessment process.
Hormesis in the Derivation of
Health Guidance Values
Regarding the third question posed in
"Introduction," the ATSDR has long been
aware ofthe complexity ofissues associated
with those toxic agents that also exhibit
beneficial effects at low exposure levels. To
date, approximately 275 chemical contami-
nants commonly found at hazardous waste
sites have been categorized and ranked by
the ATSDR according to toxicity, fre-
quency of occurrence, and potential for
human exposure (37). Many ofthese sub-
stances have been shown to be toxic at high
exposure levels but appear to be beneficial
at much lower exposure levels. Such sub-
stances include not only dietary essential
trace elements such as manganese, fluoride,
chromium, zinc, and selenium but also a
diverse spectrum ofpurported hormetic
agents such as carbon tetrachloride, chloro-
form, cyanide, heavy metals, polychlori-
nated biphenyls, and insecticides (38,39).
Because many ofthese substances are com-
mon contaminants at a number of toxic
waste sites, they present a variety ofunique
problems for public health assessments at
those sites.
As previously mentioned, the ATSDR
carefully considers the biological effects
of low-level exposures in its human
health assessments, particularly in those
deliberations involving the derivation of
MRLs. Any evidence of hormesis (i.e.,
the induction of beneficial effects by low
doses of otherwise harmful physical or
chemical agents) has always been carefully
noted and considered in these delibera-
tions. However, even though the concept
ofhormesis has been the subject ofexten-
sive scientific debate in recent years
(40,41), it still is not known whether
hormetic effects occur with most toxico-
logical end points (e.g., carcinogenesis,
immunotoxicity, mutagenesis, teratogen-
esis) or whether hormetic effects occur at
the same site of action for both low and
high levels ofexposure.
Nonetheless, the fact remains that many
chemicals on the ATSDR list ofhazardous
substances known to be toxic at high expo-
sure levels can cause deficiency associated
toxicity ifexposure levels are extremely low
or absent (e.g., chromium, manganese,
zinc). For each substance in its MRL delib-
erations the ATSDR considers not only
high-dose toxicity but also any evidence of
essentiality or beneficial effects as well as any
evidence ofdeficiencyassociated toxicity.
The best known and understood
chemical substances identified as beneficial
at extremely low doses are dietary essential
trace element(s) (ETE), i.e., chemical sub-
stances that must be present in small quan-
tities in the human diet to maintain normal
physiological functions. For each ETE, two
ranges ofexposure or intake are associated
with adverse health effects: intakes that are
too low and result in nutritional deficiency
and intakes that are too high and cause
toxicity. Some examples of the types of
information considered by the ATSDR in
derivation oforal MRLs for a number of
ETEs are discussed below.
Chromium
Chromium enters the environment in
several different forms. Cr(III) is an essen-
tial nutrient that acts as a cofactor for
insulin and helps the body use sugar, pro-
tein, and fat (required for normal energy
metabolism). Cr(VI), however, generally is
considered harmful and is produced only
from anthropogenic sources. Usually a sub-
stantial margin ofsafety exists between the
amount ofCr(III) normally consumed and
the amount considered to have harmful
effects. High levels of Cr(VI) have been
reported to increase the incidence of
bronchial cancer in workers exposed to
chromate dusts (42) and to cause sensitiza-
tion, asthma, and dermatitis. Humans can-
not oxidize the nontoxic Cr(III) to the
potentially carcinogenic Cr(VI); however,
Cr(VI) can be reduced to Cr(III) after
penetration of biological membranes and
in the gastric environment and therefore
there has been some difficulty in distin-
guishing between the effects ofthe two Cr
forms (43).
In a number ofanimal studies severe Cr
deficiency in animal studies has resulted in
hyperglycemia, decreased weight gain,
elevated serum cholesterol levels, aortic
plaques, corneal opacities, impaired fertil-
ity, and lethality (43). For humans the
estimated safe and adequate daily intake
(ESADDI) is 50 to 200 pg (44). In high-
dose studies in mice with either chromium
sulfate or potassium dichromate, the most
sensitive toxic end point observed was
decreased spermatogenesis (45). However,
this end point was classified by theATSDR
as a serious effect and therefore inappropri-
ate for derivation of an MRL (3,43).
Because ofthe lack ofdata appropriate for
deriving an MRL, theATSDRadopted the
upper limit of the ESADDI-200 pg
Cr/day-as an interim health guidance
value for Cr(III) and Cr(aVI). Such guid-
ance was deemed both appropriate and
necessary because ofthe prevalence ofCr at
hazardous waste sites, the fairly complete
database on Cr, and the fact that Cr is an
essential nutrient.
Manganese
Manganese is a constituent of several
metalloenzymes (arginase, pyruvate carboxy-
lase, and manganese superoxide dismutase)
and an enzyme activator (hydrolases,
kinases, decarboxylases, and transferases)
(44,46,47). It is required for normal brain
function. Although Mn is an essential nutri-
ent, exposure to high levels through inhala-
tion or ingestion may cause adverse health
effects. Inhalation ofhigh Mn concentra-
tions in dust or fumes, not dietary intake, is
the primary exposure route associated with
toxicity in humans (48). Toxicity in
humans can be manifest as a crippling neu-
rologic disorder ofthe extrapyramidal sys-
tem, with morphological lesions reminiscent
ofParkinson's disease (49). In addition to
nervous system damage, reproductive and
immune dysfunction, nephritis, testicular
damage, pancreatitis, lung disease, and
hepatic damage can also occur (49). In
domestic animals iron deficiency has also
occurred as a result ofthe inhibitory effect
ofMn on iron absorption (50). Conversely,
Mn deficiency results in poor reproductive
performance, growth retardation, congenital
malformations in offspring, abnormal
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formation of bone and cartilage, and
impaired glucose tolerance (50).
The ESADDI for Mn intake for adults
is 2 to 5 mg/day (44). Because appropriate
data are lacking, no oral MRLs have been
derived for either acute-, intermediate-, or
chronic-duration exposure to Mn. As a
result the ESADDI upper limit of 5
mg/kg/day was used to derive an interim
health guidance value of 0.07 mg/kg/day
until such time that information appropri-
ate for derivation of these MRLs becomes
available (49). The ATSDR considers such
interim guidance both appropriate and
necessary because ofthe prevalence of Mn
at hazardous waste sites and the fact that
Mn is an essential nutrient.
Zinc
Zinc is an essential element for plants,
animals, and humans, and is a component
ofmany enzymes involved in major meta-
bolic pathways (44,51). Zn provides a mol-
ecular mechanism by which growth
hormone can bind to the prolactin receptor
(52). However, like all essential elements
Zn can also be toxic. Small incremental
changes in Zn intake can have significant
effects on the absorption ofboth copper and
iron in some individuals (53,54). Ingestion
ofexcess Zn depresses superoxide dismutase
levels in humans (55). Supplementation
with amounts many times the recom-
mended daily allowance (5) resulted in
impairment ofvarious immune responses
(56) and caused a decline in high-density
lipoproteins in serum (57). Conversely, Zn
deficiency causes growth and developmen-
tal retardation in humans (58,59), reduced
immune function (60), and reproductive
failure and teratogenesis in animals (51).
Young men with Zn deficiency exhibited
hypogonadism with impaired development
ofsecondary sexual characteristics (58);
general signs and symptoms in humans
include loss ofappetite, slow wound heal-
ing, decreased sense oftaste and smell, and
dermatological problems.
The ATSDR derived an intermediate
oral MRL of0.3 mg Zn/kg/day based on
hematologic effects, including decreased
hematocrit, serum ferritin, and erythrocyte
superoxide dismutase activity, in women
given daily supplements of Zn as Zn glu-
conate for 10 weeks (54,61). Normally for
derivations ofthis type a UF of 100 would
have been used (10 for sensitive human pop-
ulations and 10 for the use of an LOAEL
instead of an NOAEL) (3). However,
because this LOAEL was considered to be
a minimal LOAEL (3,61) and because Zn
is an essential nutrient, a total UF of3 was
used instead of the normally applied 100.
The 0.3 mg Zn/kg/day MRL thus derived
has also been adopted as a chronic oral
MRL because of a lack ofadequate long-
term studies in either humans or animals.
This value is expected to be without adverse
effects when Zn is consumed at this level on
a daily basis over a long period oftime and
neither induces nutritional deficiency in
healthy, nonpregnant adults ingesting the
averageAmerican diet nor causes toxicity.
Future Directions
In addition to the three mechanistic areas
of consideration discussed above, the
ATSDR is aware ofa number ofadditional
methodological issues that also affect its
risk analysis processes. To address these
issues theATSDR is developing and imple-
menting a number of additional programs
specifically designed to reduce the uncer-
tainties in its public health assessments,
improve the accuracy of its MRL, and
provide additional interim health-based
guidance values. These efforts include evalu-
ation ofthe potential impact ofphysiologi-
cally based pharmacokinetic (PBPK)
modeling and benchmark dose (BMD)
modeling on the development of MRLs.
TheATSDR is also assessing specific chem-
icals and chemical mixtures using an in
vitro functional screening approach. In
addition, the ATSDR is evaluating chemi-
cal interactions in the expression oftoxicity
from exposure to chemical mixtures.
PBPKModeling
The ATSDR's PBPK modeling approach
consists ofapplying knowledge about bio-
logic mechanisms to the calculation of
toxic chemical dosimetry in target tissues
from external exposure concentrations
(62). PBPK modeling recently performed
by the ATSDR revealed that when a chem-
ical is rapidly metabolized to a relatively
less toxic intermediate, the current ATSDR
MRL methodology (3) may overestimate
the relative human hazard. For example,
the ATSDR's acute inhalation MRL of0.4
parts per million (ppm) for methylene
chloride (63) was derived from an LOAEL
of 300 ppm for central nervous system
(CNS) effects (decreased neurobehavioral
performance) in humans (64) adjusted to
continuous exposure and divided by a UF
of 100 (10 for use of an LOAEL and 10
for human variability). In comparison,
PBPK modeling provided pharmacokinetic
dose metrics for methylene chloride in the
blood for both peak concentration and area
under the concentration curve (65). By
dividing each of these resulting dose met-
rics by the same UF of 100, an acute inhala-
tion PBPK-based MRL for methylene
chloride was calculated to be either 6 or
0.8 ppm, respectively, depending on the
dose metric used. Acute CNS effects for
solvents such as methylene chloride display
both rapid onset and rapid reversibility and
are likely to result from a direct effect of
the parent chemical on the CNS. Rapid
metabolism ofmethylene chloride to a less
toxic intermediate would tend to reduce
acute toxicity by lowering the amount of
the parent chemical in the body, thereby
leaving less active parent chemical to inter-
act with the CNS. Such information and
logic would thus support the higher acute
inhalation MRL for methylene chloride
derived through PBPK modeling.
If toxicity is attributable to a stable
metabolite, however, the current ATSDR
MRL methodology may actually underesti-
mate the relative human hazard. For exam-
ple, the ATSDR's current acute oral MRL
of 0.5 mg/kg/day for TCE was derived
from an LOAEL for developmental effects
in mice (66) divided by a UF of 100 (10
for use ofan LOAEL and 10 for animal to
human extrapolation) (17). In comparison,
PBPK modeling of TCE (67) provided
dose metrics for the area under the concen-
tration curve for both the parent chemical
and the metabolite, TCA. Dividing these
dose metrics by a UF of30-10 for use of
an LOAEL and 3 for animal-to-human
extrapolation (instead of 10 because ofthe
reduced uncertainty provided by pharmaco-
kinetic modeling)-an acute oral MRL for
TCE was calculated to be either 0.02
mg/kg/day based on the TCE dose metric
or 0.04 mg/kg/day based on the TCA dose
metric. Because the TCA metabolite tends
to accumulate in the fetus through an ion-
trapping mechanism and acts as a teratogen
by coagulating fetal proteins, this would
support the application of PBPK modeling
to lower the acute oral MRL for TCE.
BenchmarkDoseModeling
The ATSDR is also evaluating the utility
of BMD modeling to obtain low-inci-
dence response exposure levels calculated
from mathematically fitted dose-response
curves as an adjunct to the current
NOAEL/LOAEL approach in developing
MRLs. A BMD is defined as "a statistical
lower confidence limit for a dose that pro-
duces a predetermined change in the
response rate of an adverse effect com-
pared to background" (68). The BMD
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approach is not restricted to experimental
NOAELs/LOAELs but also makes use of
dose-response data and sample size (69).
Because the purpose ofthe BMD model is
to derive an estimate ofdose for a given
incidence that is likelyto fall within aprede-
termined experimental dose range, and
because the model does not require extrapo-
lation to estimates far below the experimen-
tal dose range, the degree ofuncertainty in
the dose estimates is lessened. Depending
on the end point and acceptable response
level selected, using the BMD model may
obviate the need for a default UF of 10 for
LOAEL-to-NOAEL extrapolation (68,70).
The ATSDR's current intermediate
oral MRL of0.002 mg/kg/day for inor-
ganic mercury was based on an NOAEL
for increased kidney weight in rats divided
by a UF of 100 (10 for animal-to-human
extrapolation and 10 for human variability)
(71). In a BMD analysis ofinorganic mer-
cury studies recently conducted by the
ATSDR, relative kidneyweight was used as
the response to calculate BMDs from the
same study using the Weibull model.
Application of 100-fold UF for intra- and
interspecies variability yielded the follow-
ing BMD-based intermediate oral MRL for
inorganic mercury: 0.003 mg/kg/day for an
estimated 10% risk, 0.002 mg/kg/day
for an estimated 5% risk, and 0.0003
mglkg/dayfor an estimated 1% risk.
In this case, the BMD-based intermedi-
ate oral MRL for an estimated 5% risk was
the same as theATSDR's current MRL.
FunctionalToxicology
Through an interagency agreement with
the National Institute ofEnvironmental
Health Sciences, the ATSDR is pursuing
development of functional toxicology
assays to screen chemicals. These screens
are comprised of human or animal cell
lines transfected with a specific receptor
gene along with a reporter gene. The pur-
pose ofthese in vitro screens is to provide
an assessment ofthe degree to which a sin-
gle chemical or chemical mixture might
exhibit some specific functional activity
(e.g., estrogenic activity or dioxinlike activ-
ity). It is hoped that this approach eventu-
ally will permit priority chemicals and/or
chemical mixtures to be evaluated on the
basis offunctional activity such as receptor
binding, receptor occupancy, or gene acti-
vation rather than traditional whole-animal
bioassay results (72).
Chemical Interactions
The ATSDR, in collaboration with the
TNO Nutrition and Food Research
Institute, The Netherlands, is conducting
studies to evaluate the role of chemical
interactions in the expression of toxicity
from low-level exposure to combinations of
chemicals. A weight-of-evidence (WOE)
approach (73) is used to predict the toxic-
ity ofsome simple chemical mixtures based
on published literature reports then com-
pare these predictions with test results from
actual animal toxicity studies. The WOE
evaluation process uses individual chemical
dose-response assessments and algorithms
that incorporate various assumptions
regarding potential chemical interactions.
Qualitative (type oftoxicity) and semi-
quantitative (direction ofresponse not spe-
cific magnitude) evaluations have been
prepared on binary weight-of-evidence
combinations ofchemicals included in two
four-component mixture studies conducted
by the TNO. These evaluations were used
to estimate the overall toxicities ofthe mix-
tures that were then compared with experi-
mentally determined toxicities (74,75).
Preliminary analyses ofthe data indicate
that the WOE approach quantitatively
accounts for the observed interactions for
mixtures ofsimilarly acting renal toxicants,
but for dissimilarly acting renal toxicants
the method performs less well. This could
be attributed to the fact that WOE evalua-
tions are based on dose additivity that pos-
tulates that all chemicals in a given mixture
act in the samewaybythe same mechanism
and differonly in theirpotencies. Therefore,
although this approach may be inappropri-
ate for evaluating interactions for dissimilar
acting agents, it may hold promise as a
means to identify agents having different
mechanisms ofaction.
Conclusions
The ATSDR believes that because it is a
public health agency it is vitally important
to continue to expand and improve its
understanding and practical application of
mechanistic principles to the risk analysis
of hazardous environmental exposures.
Mechanistic factors that must be consid-
ered in this process include specific chemi-
cal speciation, bioavailability, toxicokinetics
and toxicodynamics, adaptive responses,
hormesis and essentiality, and interactive
effects of chemical mixtures. As was pre-
viously pointed out in Johnson and Jones
(76), it is essential to continue to invest
in programs that expand our understand-
ing ofthese mechanisms so that both our
"risk assessments and science policies can
be adjusted in light of new and better
scientific data."
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